To determine the role of bone marrow-derived cells in restoration of neonatal lung structure after injury, we studied a novel bone marrow myeloid progenitor cell population from Tie2-green fluorescent protein (GFP) transgenic mice (bone marrow-derived angiogenic cells; BMDAC). We hypothesized that treatment with BMDAC would restore normal lung structure in infant mice during recovery from neonatal hyperoxia. Neonatal mice (1-day-old) were exposed to 80% oxygen for 10 days. BMDACs (1 ϫ 10 5 ), embryonic endothelial progenitor cells, mouse embryonic fibroblasts (control), or saline were then injected into the pulmonary circulation. At 21 days of age, saline-treated mice had enlarged alveoli, reduced septation, and a reduction in vascular density. In contrast, mice treated with BMDAC had complete restoration of lung structure that was indistinguishable from room air controls. BMDAC comprised 12% of distal lung cells localized to pulmonary vessels or alveolar type II (AT2) cells and persist (8.8%) for 8 wk postinjection. Coculture of AT2 cells or lung endothelial cells (luEC) with BMDAC augmented AT2 and luEC cell growth in vitro. We conclude that treatment with BMDAC after neonatal hyperoxia restores lung structure in this model of bronchopulmonary dysplasia. bronchopulmonary dysplasia; stem cell; oxygen; alveolar type 2 cell; endothelial cell PREMATURE BIRTH AND THE TREATMENT of respiratory distress syndrome with oxygen and mechanical ventilation leads to the development of chronic lung disease known as bronchopulmonary dysplasia (BPD; Ref. 45). BPD is characterized by persistent abnormalities of lung structure due to dysmorphic vascular growth and impaired alveolarization (13, 32). Structural lung abnormalities in infants with BPD include a reduction of lung surface area, resulting in abnormal gas exchange, exercise intolerance, and pulmonary hypertension (2, 13, 28, 31, 51, 52) . Oxygen toxicity in the developing lung contributes to the pathogenesis of BPD, but mechanisms by which hyperoxia induces lung injury and impairs lung repair are unclear (62, 63, 65) .
bronchopulmonary dysplasia; stem cell; oxygen; alveolar type 2 cell; endothelial cell PREMATURE BIRTH AND THE TREATMENT of respiratory distress syndrome with oxygen and mechanical ventilation leads to the development of chronic lung disease known as bronchopulmonary dysplasia (BPD; Ref. 45) . BPD is characterized by persistent abnormalities of lung structure due to dysmorphic vascular growth and impaired alveolarization (13, 32) . Structural lung abnormalities in infants with BPD include a reduction of lung surface area, resulting in abnormal gas exchange, exercise intolerance, and pulmonary hypertension (2, 13, 28, 31, 51, 52) . Oxygen toxicity in the developing lung contributes to the pathogenesis of BPD, but mechanisms by which hyperoxia induces lung injury and impairs lung repair are unclear (62, 63, 65) .
Previous studies have shown that postnatal lung injury during the alveolar stage of lung development disrupts both alveolar and vascular growth (44, 48, 49, 53, 64) . In addition, disruption of vascular growth during the alveolar stage is sufficient to impair septation, leading to marked simplification of the distal lung structure (30, 40) . Neonatal hyperoxia exposure provides a useful model to study BPD (20, 66) . Studies using extreme hyperoxia (Ͼ95% O 2 ) have demonstrated a striking inhibition of distal lung growth that persists during infancy and into adulthood, as evidenced by increased distal air space size with reduced septation and decreased vascular density (18, 19, 38, 41, 48, 49, 62, 64) . Moderate hyperoxia (60 -65% O 2 ) has also been shown to inhibit lung vascular and alveolar growth in neonatal rodents (8, 11, 15, 23) . These changes in lung structure closely mimic the histology of altered lung architecture observed in human infants with BPD (13, 28, 31, 32, 51, 52) , thereby providing a useful experimental model for studying BPD.
Hyperoxia may impair lung growth by multiple mechanisms, including effects on circulating and endogenous progenitor cell populations. Circulating bone marrow-derived endothelial progenitor cells (EPC) play a role in the repair of several organs after vascular injury by promoting neovascularization in the heart (4, 34), brain (69) , and ischemic hindlimb (5, 33) of adult animals. We have previously observed that neonatal mice demonstrate emphysematous changes in lung structure after exposure to moderate levels of hyperoxia, whereas the same level of hyperoxia does not affect lung structure of adult mice (8) . Levels of EPC were reduced in the blood, bone marrow, and lungs of infant mice exposed to hyperoxia but increased in adult mice exposed to hyperoxia (8) . Furthermore, in this model, suppression of the bone marrow of the adult mouse by irradiation confers a susceptibility to hyperoxia-induced alterations of lung structure, thus suggesting a role for a bone marrow-derived cell population in the maintenance of lung structure in the adult exposed to hyperoxia (8) . Bone marrow-derived mesenchymal stem cell (MSC) treatment has been suggested as a therapy for ischemic heart disease (29, 61) and as a potential therapy for stroke (54) . These studies suggest that the targeting of increasing levels of circulating bone marrow-derived progenitors may be a therapeutic strategy for the restoration of various organs after injury.
Local endogenous populations of "stem" or progenitor cells have been identified in the different regions of the respiratory tract (27) . These cells include the basal epithelial cells in the trachea and bronchi (26) , CC10-positive Clara cells in the bronchiolar airways and neuroepithelial bodies (21, 26, 46, 47) , and the alveolar type II (AT2) cell for the lung parenchymal epithelium (43) . There has been controversy whether these populations of endogenous lung cells have the proliferative capacity to repair the lung epithelial structure to prevent the progression of lung disease after injury (55) . The regeneration or stimulation of AT2 cell growth has been the focus of regeneration of the distal lung (1, 36, 67) . All of these studies, to date, have been performed in the adult animal focusing on the contribution of exogenous lung cells to the epithelial component of the lung. The role of circulating cell populations in normal postnatal lung growth, the role of circulating cells in a model of chronic impaired lung growth such as after neonatal injury, and the role of circulating cells after neonatal injury have not been studied.
In the present study, we hypothesized that a population of angiogenic bone marrow-derived cells (BMDAC) exists in mice that would enhance the recovery of lung alveolar and vascular structure after neonatal hyperoxia exposure. Using a method to isolate EPCs from the mouse embryo (25), Tie2-expressing cells from the bone marrow of Tie2-green fluorescent protein (GFP) transgenic mice were isolated and characterized as a novel myeloid progenitor that expresses angiogenic markers. We named these cells BMDACs. BMDACs were successfully expanded in vitro and infused into the pulmonary circulation after neonatal hyperoxic injury. In contrast to control mice that demonstrated a persistence of impaired lung growth, BMDAC treatment after neonatal hyperoxia improved lung structure such that it was indistinguishable from room air-raised control mice. Furthermore, BMDACs did not differentiate into lung epithelial or endothelial cells but rather engrafted in close approximation to a known lung epithelial progenitor cell, the AT2 cell. These findings suggest a critical role for bone marrow-derived cells in the recovery of lung growth and structure after neonatal injury.
METHODS
Study animals and protocols. All procedures and protocols were reviewed and approved by the Animal Care and Use Committee at the University of Colorado Health Sciences Center. Mice (FVB/N background) were obtained from The Jackson Laboratories and bred in-house.
Hyperoxia exposure. Litters from pregnant mice were allowed to deliver and recover in room air for 24 h after birth. Mother and litters were placed in chambers in which the oxygen concentration was maintained at a fraction of inspired oxygen (FI O 2 ) of 0.8, achieving an alveolar PO2 (PaO 2 ) of 466 mmHg at Denver altitude [barometric pressure (PB) ϭ 630 mmHg; equivalent to a FIO 2 of 0.65 at sea level] for 10 days or maintained in room air (Fig. 1 ). Exposure to hyperoxia was continuous, with brief interruptions only for animal care (Ͻ10 min/day). The concentration of oxygen was maintained by the use of an oxygen controller (ProOx; Reming Bioinstruments). At the end of the hyperoxia exposure, animals received an injection of BMDAC (1 ϫ 10 5 ), embryonic EPCs [eEPCs; 1 ϫ 10 5 ; from Dr. A. K. Hatzopoulos (25) ], mitomycin C-treated mouse embryonic fibroblasts (MEF), or saline into the pulmonary circulation via injection through the right ventricle. Successful injection into the right ventricle was verified by visualization of the injection site at time of euthanasia. The pups and mothers were then placed in cages in room air. Lung tissue was harvested at 3 and 8 wk of age for immunofluorescence and morphometric analysis.
eEPCs. eEPCs were a kind gift from Dr. A. K. Hatzopoulos and were cultured as previously described (25) . eEPCs were cultured from embryonic day 7.5 embryos on a feeder layer of irradiated MEF and were shown to express endothelial markers, have a classic cobblestone appearance, make tubular structure when cultured on Matrigel, and incorporate into the vasculature of the brain and endocardium (25) .
Isolation and culture of BMDAC. We adapted a technique that has been used to isolate EPCs from the mouse embryo in an attempt to isolate angiogenic cells from the bone marrow of adult transgenic mice that express GFP under the control of the Tie2 promoter [STOCK Tg(TIE2GFP)287Sato/J; The Jackson Laboratories]. Given the continued expression of the angiogenic marker, Tie2, these cells were called BMDACs. Adult (6 -8 wk old) Tie2-GFP mice were euthanized by CO 2 asphyxiation, and the femur and tibia were removed. The ends of the bones were cut off, and the marrow was flushed with saline. The mononuclear fraction was isolated by density gradient centrifugation on Ficoll-Hypaque at 740 g for 10 min. These cells were transferred to tissue culture dishes onto a monolayer of MEF, which had been previously treated with mitomycin C (Roche) to inhibit MEF proliferation. After 2 wk in culture, colonies of cells that expressed Tie2 were identified by GFP fluorescence (Fig. 2 ) and transferred to new dishes with feeder layers of MEFs for expansion. These cells were then subjected to FACS and also injected into the infant mice.
FACS characterization of BMDAC. BMDACs were stained for the following antibodies and their appropriate isotype antibody control: CD133-biotin (eBioscience, San Diego, CA), Sca-1-biotin (BD Biosciences, San Diego, CA), KDR-PE (BD Biosciences), CD34-APC (BD Biosciences), CD45-APC (BD Biosciences), CD44-PE (BD Biosciences), CD38-PE (BD Biosciences), CXCR4-PE (BD Biosciences), Tie2-PE (eBioscience), Ly-6G/C-PE (BD Biosciences), CD11a-PE (BD Biosciences), CD11b-PE (BD Biosciences), F4/ 80-PE (BD Biosciences), and c-Kit receptor-PE (BD Biosciences). The cells were analyzed with a Beckman Coulter (Miami, FL) Epics XL Flow Cytometer at the University of Colorado Health Sciences Flow Cytometry Core Laboratory. Voltage compensation for fluorescence intensity was performed with the use of CompBeads (cat. no.
552844; BD Biosciences).
Methylcellulose colony-forming assay. To characterize the potential of BMDAC to differentiate along a hematopoietic lineage, cells were seeded at a density of 1 ϫ 10 5 in a mouse colony-forming assay kit (MethoCult GF M3534; Stem Cell Technologies) that contained recombinant murine (rm) stem cell factor (rmSCF; 50 ng/ml), rmIL-3 (10 ng/ml), rmIL-6 (10 ng/ml), erythropoietin (EPO; 3 U/ml), granulocyte colony-stimulating factor (G-CSF; 10 g/ml), and granulocyte/macrophage colony-stimulating factor (GM-CSF; 10 g/ml). After 14 days in culture, colonies were identified per manufacturer's instructions. Additionally, representative colonies were removed from the methylcellulose to a glass slide and stained with May-Grünwald stain (cat. no. 660/75; EM Diagnostics) and Giemsa stain (cat. no. 620/75; EM Diagnostics), and cells were characterized by light microscopy.
In vivo angiogenesis assay. Cellularized Matrigel implants were cast as previously described (68) . Cultured BMDACs (2 ϫ 10 6 ) or isolated bone marrow mononuclear cells were suspended in a solution of Matrigel (cat. no. 356235; BD Biosciences) and allowed to polymerize at 37°C for 30 min. Gels were bisected and implanted into the flank of anesthetized 12-wk-old FVB/N mice. At 14 -30 days, mice were killed, and the grafts were excised and analyzed.
Lung histology. Lungs were prepared for histology as previously described (6) . Briefly, mice were euthanized with intraperitoneal injections of pentobarbital (100 mg/kg). A catheter was placed into the trachea, and the lungs were inflated and maintained at 30 cmH 2O pressure with 4% paraformaldehyde in PBS for Ն45 min. A ligature was tightened around the trachea to maintain pressure after removal of the tracheal cannula. Lungs were immersed in paraformaldehyde solution overnight, and a 0.5-cm thick section of the left lower lobe was embedded in paraffin. Sections were cut with a microtome set at 5 m and mounted on RNase-free slides for immunohistochemical analysis. For immunofluorescence, a section of the lung was placed in gradually increasing amounts of sucrose and then transitioned to optimal cutting temperature (OCT; Tissue Tek) solution. Ten-micrometer sections were cut on a cryostat for immunofluorescence staining.
Morphometric analysis. Morphometric analysis was performed using standard techniques in our laboratory, which includes computer-assisted image analysis to assess nodal point density by skeletonization, mean linear intercept (MLI), average alveolar size, and internal surface area (Ref. 7 and data supplement online at the AJP-Lung Cellular and Molecular Physiology web site). Radial alveolar counts (RAC) were assessed by standard methods as previously described (9, 14) . Sections were stained for the presence of factor VIII [von Willebrand factor (vWF); DAKO], an endothelial-specific marker. For assessment of vessel density, images of factor VIII-stained slides were captured with the ϫ20 objective. The number of factor VIII-positive vessels (20-to 80-m diameter in size) were counted for each high-powered field.
Immunofluorescent colocalization. OCT-embedded sections were fixed in 4% paraformaldehyde for 20 min and then with acetonemethanol (1:1) solution for 15 min. The sections were washed with PBS and permeabilized with 0.1% Triton-X/PBS solution. Sections were blocked with 0.1% BSA ϩ 1% horse serum block for 1 h. The sections were then incubated overnight with a combination of two of the following antibodies overnight at 4°C: anti-GFP (1:100; AB290; Abcam), anti-CD45 (1:100; MCD4500; Caltag), prosurfactant protein C (pro-SP-C; 1:100; SC7706; Santa Cruz Biotechnology), and vWF (1:250; A0082; DAKO). After washing with PBS, sections were incubated with the appropriate secondary antibody (1:500) for 4 h at room temperature. Sections were washed and coverslipped with Vectashield and imaged with either an Olympus IX71 Inverted Fluorescence Microscope or an Olympus IX81-DSU Spinning Disk Confocal Microscope.
AT2 isolation and coculture. Mice (6 -8 wk old) were euthanized by CO2 asphyxiation. The thorax was opened, and the pulmonary circulation was flushed with sterile PBS. The lungs were excised, and distal lung tissue was minced finely and digested in 1% collagenase (Worthington Biochemical) ϩ 1 mg/ml DNase (GIBCO BRL, Carlsbad, CA) for 30 min. An equal volume of 2 mg/ml trypsin inhibitor (GIBCO BRL) ϩ 2 mg/ml DNase was added, and cell suspension was filtered through a 10-m pore diameter Nitex filter. Cells were centrifuged at 430 g for 10 min at room air temperature. Cell pellet was washed with DMEM/F-12 media and plated on nontissue culture plates coated with IgG (6 mg/cm 2 ; Sigma) for 1 h at 37°C. Nonadherent cells were recovered and centrifuged at 430 g for 10 min. Cell pellet was resuspended in DMEM/F-12 ϩ10% FBS and seeded at a density of 100,000 cells in the upper chamber of Transwell inserts with 0.4-m pore size (Corning Life Sciences, Lowell, MA). BMDACs were seeded at a density of 150,000 cells per well in the lower chamber and cultured for 4 days in room air. At the end of 4 days, cells were released with trypsin from the upper chamber, and AT2 cell number was determined by counting on a hemocytometer.
Mouse lung endothelial cell growth. Mouse lung endothelial cells (luEC) were a kind gift from Dr. Vecchi and were isolated and cultured as previously described (17) . Mouse luEC (also known as 1G11 cells) were cultured in Advanced DMEM (GIBCO BRL) with 1% penicillin-streptomycin, 1% L-glutamine, 20% FBS (HyClone), and 10 l/ml endothelial cell growth supplement (ECGS; Sigma). For proliferation coculture studies, cells were grown in the above media but with 5% FBS and with and without 2 l/ml ECGS. Mouse luEC were seeded at a density of 100,000 cells in the upper chamber of Transwell inserts with 0.4-m pore size (Corning Life Sciences). BMDACs were seeded at a density of 150,000 cells per well in the lower chamber and cultured for 4 days in room air. At the end of 4 days, cells were released with trypsin from the upper chamber, and luEC cell number was determined by counting on a hemocytometer.
Statistical analysis. Data are presented as means Ϯ SD. Statistical analysis was performed with the Prism software package (GraphPad Software, San Diego, CA). Statistical comparisons were made between groups using an ANOVA with Newman-Keuls posttest for significance.
RESULTS

Phenotypic characterization of BMDAC.
BMDACs were grown on a feeder layer of mitomycin-treated MEF. We were able to expand and passage the BMDACs, and cells (passage 1) were then characterized by FACS staining compared with isotype controls. Immunophenotyping revealed that the BMDAC express the endothelial marker, Tie2, but not VEGF receptor 2 (VEGFR2) (Fig. 3) . The BMDAC also express the hematopoietic markers CD45 and CD38 but not CD34 or a myeloid marker, CD33. BMDACs express the stem cell marker for c-Kit receptor (CD117), CXCR4, and CD44 but do not express CD11b, Sca-1, CD133 Gr-1 (Ly-6C), or CX 3 CR1. Interestingly, BMDACs express the mouse macrophage marker, F4/ 80. The BMDACs retained this cell surface phenotype up through passage 4. When cultured on methylcellulose, BMDACs differentiate into only macrophage and granulocyte populations (supplemental data). BMDACs were unable to recruit or form vascular structures in in vivo Matrigel angiogenesis assay.
BMDACs restore lung structure after neonatal hyperoxia. Neonatal exposure to moderate hyperoxia (PO 2 ϭ 466 mmHg; FI O 2 ϭ 0.65 at sea level) results in a simplified lung structure, characterized by enlarged air spaces and a reduction in the complexity of lung structure (Fig. 4, A vs. B) . Despite recovery from hyperoxia in room air for 10 days, there is a persistence of abnormal lung structure in saline-treated mice suggesting little spontaneous recovery (Fig. 4C) . Injection with BMDAC into the pulmonary circulation via injection into the right ventricle at the end of hyperoxia exposure markedly improves lung structure (Fig. 4D) . In contrast, treatment of neonatal mice with eEPCs after hyperoxia did not improve lung structure (Fig. 4E) . MEF treatment also did not improve lung structure. The restoration of lung structure after BMDAC treatment was quantified by morphometric analysis (Table 1) , which demonstrates a reduction in MLI by 13.2% (P Ͻ 0.05), an increase in nodal point density by 30% (P Ͻ 0.001), an increase in surface area by 12% (P Ͻ 0.001), an increase in RAC by 73% (P Ͻ 0.001), a reduction in average alveolar size by 35% (P Ͻ 0.001), a decrease in air space-to-parenchymal ratio by 30% (P Ͻ 0.001), and an increase in vessel density by 134% (P Ͻ 0.001). Experiments with later passage BMDACs (passages 2-5) demonstrated that treatment with late passage BMDACs continue to promote lung vascular and alveolar growth after neonatal hyperoxia. There were no significant changes in body weight or crown-rump length between any of the groups (data not shown).
Sites of BMDAC localization in the lung. In infant mice treated with BMDAC after neonatal hyperoxia, 11.8% of cells in the distal lung expressed GFP (Fig. 5A) . The level of GFP-expressing cells remained at 8.8% of distal lung cells up to 8 wk after injection (Fig. 6 ). Confocal microscopy after costaining for vWF (as a maker for endothelium) and pro-SP-B (identifying AT2 cells) revealed that BMDAC engraft in subendothelial and alveolar interstitial locations in close proximity to AT2 cells. After injection, BMDACs do not express either endothelial or alveolar epithelial cell markers (Fig. 5, B and C; for movie of confocal staining, see supplementary data). Interestingly, after injection, BMDACs do not costain for CD45 (Fig. 5D) , the macrophage marker F4/80, the pericyte marker NG2, ␣-smooth muscle actin, or vimentin (data not shown).
BMDAC promote AT2 cell growth in vitro. Coculture of AT2 cells with BMDAC increased AT2 cell number by 25% over 3 days in culture compared with AT2 cells cultured alone (Fig. 7) .
BMDAC promotes luEC growth in vitro. Proliferation of luEC is dependent on the presence of ECGS at a concentration of 2 l/ml (data not shown). Coculture of luEC cells with BMDAC increased luEC cell number by 2.8-fold compared with monoculture and equaled the growth seen with the addition of ECGS (Fig. 8) . 
DISCUSSION
We report the isolation and characterization of a novel and unique population of cells isolated from the bone marrow of adult mice, which we call BMDACs. When injected into the pulmonary circulation of infant mice, BMDAC home to the lung promoting alveolar and vascular growth after neonatal hyperoxic exposure, thus restoring lung structure to normal.
The BMDAC induced improvement in lung structure was verified by improvement in quantitative measures of lung structure, including RAC, MLI, nodal point density, and vessel density. In contrast, a known eEPC (25) was unable to promote an improvement in lung structure. BMDAC express Tie2, CD45, c-Kit receptor, CD38, CXCR4, CD44, F4/80, and lack expression of Sca-1, CD34, CD133, VEGFR2, CD11a, CD11b, Fig. 4 . BMDACs enhance alveolar growth during recovery in room air after exposure to neonatal hyperoxia. An example of lung histology of 11-day-old mouse exposed to room air (A) and hyperoxia (B). Improved alveolar structure is seen in 3-wk-old mice after injection of bone marrow-derived cells during recovery from neonatal hyperoxia (D) compared with saline-treated animals (C). Animals treated with eEPCs (E) have a persistence of enlarged air spaces compared with saline controls (C). n ϭ 8 animals in each group. Scale bar ϭ 100 m. Ly-6C, and CX 3 CR1. In addition, the BMDACs can differentiate into granulocytes and macrophages but not erythroid, lymphoid, or megakaryocytic progenitors in a methylcellulosebased assay. These findings suggest that BMDAC are a novel myeloid progenitor cell with striking capacity to promote lung growth after neonatal injury.
These findings are interesting because we have been able to identify and expand a novel population of bone marrow-derived cells that promote the recovery of lung structure after neonatal injury in infant mice. BMDACs retain their cell surface phenotype in culture for several passages and retain the potential for inducing reparative lung growth. Previous studies have suggested that bone marrow-derived cells may engraft in the lung (36) and participate in the recovery of lung structure in the adult after injury (1, 67) . A series of experiments utilizing the reconstitution of bone marrow by a single hematopoietic stem cell (HSC) resulted in a reconstitution of the lung epithelium by bone marrow-derived cells. This initial report suggested that up to 20% of AT2 cells and 4% of airway epithelial cells were derived from the single transplanted donor HSC (36) . This rate of engraftment was called into question (12) , as was the concept of the derivation of lung epithelial cells from bone marrow progenitors, in experiments using confocal and deconvolution microscopy. Marrow-derived cells found in the lung all coexpressed the hematopoietic marker CD45 after single HSC transplantation (59) . The use of deconvolution microscopy and costaining identified that marrow-derived, GFP-expressing cells in the lung were in close approximation to AT2 cells but did not coexpress the AT2 marker, SP-C (12, 35) . Our current study also demonstrates the lack of differentiation of BMDACs into alveolar epithelial cells and the close spatial approximation of this bone marrow-derived cell population to the AT2 cell.
Past studies in adult rodent models of lung disease attempted to determine the role of bone marrow-derived cells in the prevention or repair of the lung during acute injury in adult rodents. Our current study differs from these past studies in that we are utilizing a model of lung injury that disrupts normal lung development in neonatal mice as opposed to adult mice. In addition, this study examines the potential of bone marrow-derived cells to restore lung structure after disruption of alveolar and vascular development. BMDAC (or its progeny) persist in the lung, as these cells were detected in mice up to 8 wk after injection. BMDACs localize to subendothelial and alveolar interstitial locations in close approximation to endothelial cells and AT2 cells, respectively, but do not appear to differentiate into endothelial or alveolar epithelial cells. After engraftment, the BMDAC does not continue to express the hematopoietic marker CD45 nor the macrophage marker F4/80. In addition, these cells do not express the pericyte marker NG2, after engraftment. The change in expression of cell surface markers suggests that the BMDAC may differentiate into to a previously uncharacterized mesenchymal lung cell type. Treatment of infant mice after hyperoxia with exogenous bone marrow-derived cells, BMDACs, may overcome a potential inability of neonates to mobilize progenitor cells, as we observed with EPCs (8) , and stimulate the process of catch-up lung growth. The BMDAC may potentially act via a paracrine mechanism, as evidenced by their close approximation to known sites of endogenous lung progenitor populations. The ability of the BMDAC to augment growth of a known lung epithelial progenitor, the AT2 cell, in vitro suggests that the BMDAC might secrete a paracrine factor that promotes AT2 cell growth. In addition, BMDAC are able to augment the growth of endothelial cells in vitro. In our current study, we have further evidence that the capacity for catch-up growth exists in the lung after neonatal injury, as we have previously shown using the eNOS deficient mouse (7), inhaled nitric oxide after neonatal hyperoxia (41) , and VEGF treatment during and after neonatal hyperoxia (36, 39) . These studies suggest that neonatal hyperoxia results in an arrest of lung growth, yet the infant lung retains the potential for catch-up growth. It is unclear of the mechanism by which BMDAC stimulates or participates in the process of catch-up lung growth and remains one of the areas of focus of future investigation of our laboratory.
Marrow-derived cells, both in the circulation and resident in tissues, have been suggested to play a role in neoangiogenesis and growth. These cells have been best-characterized promoting neoangiogenesis in the tumor microenvironment (16, 42, 50) . These cells have been characterized as a myeloid lineage cell population that, in the appropriate microenvironment, will differentiate into a type of macrophage that promotes angiogenesis (3, 16, 22, 42, 50) . The cell surface antigen profile of the BMDAC suggests that this is a myeloid progenitor cell. Although the BMDAC shares expression of some antigens in common with the tumor-associated macrophage (TAM; Ref. 42) , the lack of CD11b and Ly-6C (Gr-1) expression in the BMDAC suggests that the BMDAC is a novel cell type and not the previously described myeloid cells or TAM (10, 56, 57) . Another population of cells that have been described, the Tie2-expressing monocyte (TEM), shares the expression of Tie2 with the BMDAC, but, like the TAMs, the TEMs also express CD11b (16, 58) . These data taken together with the surface antigen profile we have observed suggest that the BMDAC population that we have isolated is a novel cell population. One potential limitation of this study is that during the process of differentiation, the BMDAC-derived cell may stop expressing Tie2, and therefore we may underestimate the number of these cells in the lung after injection and would not be able to completely rule out the possibility that BMDACderived cells have differentiated into other lung cell types. It is also possible that BMDACs home to the bone marrow and differentiate into another cell population that is active in the restoration of lung alveolar and vascular structure. If either of these were the case, we would not expect such a high level of these Tie2-expressing cells in the lung. Additionally, the injected BMDAC may differentiate into different cell types depending on their location in the lung. Finally, this level of Tie2 expression could represent cell fusion (60), but there have been conflicting data presented as to the incidence and relevance of fusion in the lung (24) .
We conclude that a population of myeloid-like progenitor cells exists in the bone marrow that have the capacity to engraft into the infant lung after neonatal hyperoxic lung injury and promote alveolar and vascular growth. This is the first report of this novel population of cells that we have named BMDACs given their continued expression of the angiogenic marker, Tie2. BMDACs promote lung growth after neonatal injury at an accelerated pace that allows for catch-up growth of lung structure and exhibit long-term persistence in the lung. The BMDAC undergoes differentiation in the lung to a previously unidentified interstitial cell that does not express endothelial, epithelial, smooth muscle, or hematopoietic markers. We speculate that this population of cells is mobilized from the bone marrow and may be responsible for the tolerance of the adult mouse to moderate hyperoxia exposure. Furthermore, the BMDAC is not mobilized in the neonate exposed to hyperoxia, thus conferring the increased susceptibility of the neonate to moderate hyperoxia. Impaired BMDAC mobilization, homing, or function may contribute to the persistence of abnormal vascular and alveolar structure in infants with BPD.
